Stem Cells http://www.epitomics.com
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


First published online August 18, 2005
Stem Cells Vol. 23 No. 10 November 2005, pp. 1589 -1597
doi:10.1634/stemcells.2005-0049; www.StemCells.com
© 2005 AlphaMed Press

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
2005-0049v1
2005-0049v2
23/10/1589    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Reprints/Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Iwasaki, M.
Right arrow Articles by Ikehara, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Iwasaki, M.
Right arrow Articles by Ikehara, S.

Hepatocyte Growth Factor Delivered by Ultrasound-Mediated Destruction of Microbubbles Induces Proliferation of Cardiomyocytes and Amelioration of Left Ventricular Contractile Function in Doxorubicin-Induced Cardiomyopathy

Masayoshi Iwasakia,b, Yasushi Adachia,c, Takashi Nishiueb, Keizo Minaminoa, Yasuhiro Suzukia, Yuming Zhanga, Keiji Nakanoa, Yasushi Koikea, Jianfeng Wanga, Hiromi Mukaidea, Shigeru Taketanid, Fumio Yuasab, Hirohito Tsubouchie, Eiichi Gohdaf, Toshiji Iwasakab,c, Susumu Ikeharaa,c

a First Department of Pathology,
b Second Department of Internal Medicine,
c Regeneration Research Center for Intractable Diseases, Kansai Medical University, Osaka, Japan;
d Department of Biotechnology, Kyoto Institute of Technology, Kyoto, Japan;
e Department of Internal Medicine II and Faculty of Medicine, University of Miyazaki, Miyazaki, Japan;
f Faculty of Pharmaceutical Science, Okayama University, Okayama, Japan

Key Words. Hepatocyte growth factor • Doxorubicin-induced cardiomyopathy • Ultrasound-mediated destruction of microbubbles • Cardiac progenitor cell

Correspondence: Susumu Ikehara, M.D., Ph.D., First Department of Pathology, Kansai Medical University, 10-15 Fumizono-cho, Moriguchi City, Osaka 570-8506, Japan. Telephone: 81-6-6993-9429; Fax: 81-6-6994-8283; e-mail: ikehara{at}takii.kmu.ac.jp

At present, there is no curative strategy for advanced cardiomyopathy except for cardiac transplantation, which is not easily performed, mainly due to a shortage of donors. It has been reported that myocardial progenitor cells exist even in the postnatal heart, suggesting that myocardial progenitor cells could proliferate under some situations and might improve cardiac function in cardiomyopathy-induced hearts. In this study, recombinant human hepatocyte growth factor (rhHGF) was delivered using ultrasound-mediated destruction of microbubbles (UMDM) into the cardiomyopathy-induced heart by doxorubicin (20 mg/kg). Intravenous injection of rhHGF (IV-rhHGF) alone or UMDM alone failed to improve the morphology or the function of the cardiomyopathy-induced heart, but (IV-rhHGF + UMDM) treatment significantly improved the heart morphologically and functionally, and repetitive treatments of (IV-rhHGF + UMDM) enhanced the effects. The number of bromodeoxy-uridine-positive cardiomyocytes significantly increased in the (IV-rhHGF + UMDM)–treated hearts compared with the untreated hearts. Moreover, Sca-1+ myocardial progenitor cells express c-Met, a receptor for HGF. These results suggest that (IV-rhHGF + UMDM) treatment could morphologically and functionally improve the heart in the case of doxorubicin-induced cardiomyopathy through the proliferation of the myocardial progenitor cells.




This article has been cited by other articles:


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
M. Esaki, G. Takemura, K.-i. Kosai, T. Takahashi, S. Miyata, L. Li, K. Goto, R. Maruyama, H. Okada, H. Kanamori, et al.
Treatment with an adenoviral vector encoding hepatocyte growth factor mitigates established cardiac dysfunction in doxorubicin-induced cardiomyopathy
Am J Physiol Heart Circ Physiol, February 1, 2008; 294(2): H1048 - H1057.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
C. Bardella, D. Dettori, M. Olivero, N. Coltella, M. Mazzone, and M. F. Di Renzo
The Therapeutic Potential of Hepatocyte Growth Factor to Sensitize Ovarian Cancer Cells to Cisplatin and Paclitaxel In vivo
Clin. Cancer Res., April 1, 2007; 13(7): 2191 - 2198.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
STEM CELLS THE ONCOLOGIST CME ALPHAMED PRESS JOURNALS
http://www.stemcellsportal.com/
Copyright © 2005 by AlphaMed Press.